Conference Coverage

Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer

Publish date: June 12, 2013

 

AT THE ASCO ANNUAL MEETING 2013

LAP 07 was sponsored by Groupe Cooperateur Multidisciplinaire en Oncologie. Dr. Hammel reported honoraria from Roche.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Impact of pretreatment PET on disease control and treatment decisions in locoregionally advanced esophageal cancer patients treated with chemoradiotherapy
MDedge Hematology and Oncology
Utilization of radiotherapy services by a palliative care unit: pattern and implication
MDedge Hematology and Oncology
Onsite cytopathology improves pancreatic biopsy quality
MDedge Hematology and Oncology
FIRE-3: Cetuximab/FOLFIRI prolongs metastatic colorectal cancer survival
MDedge Hematology and Oncology
Novel genetic marker predicts pancreatic cancer risk
MDedge Hematology and Oncology
Rates of adjuvant therapy for pancreatic cancer still low
MDedge Hematology and Oncology
Urinary test shows promise for pancreatic cancer detection
MDedge Hematology and Oncology
Cohort study shows link between colonoscopy, overall mortality
MDedge Hematology and Oncology
EET and esophagectomy yield similar cancer-free survival
MDedge Hematology and Oncology
Benefits of laparoscopic over open colectomy decrease with operative time
MDedge Hematology and Oncology